Insulin Glargine versus Insulin Detemir in the Treatment of Type 2 Diabetes:A Meta-analysis
10.6039/j.issn.1001-0408.2016.18.26
- VernacularTitle:甘精胰岛素对比地特胰岛素治疗2型糖尿病的Meta分析
- Author:
Zheng FAN
;
Guiming GUO
;
Wenzhe LI
;
Ying XUE
;
Honglei WANG
;
Luyang LI
;
Wei XIAO
- Publication Type:Journal Article
- Keywords:
Insulin glargine;
Insulin detemir;
Type 2 diabetes;
Meta-analysis;
Efficacy;
Safety
- From:
China Pharmacy
2016;27(18):2524-2527
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the efficacy and safety of insulin glargine versus insulin detemir in the treat-ment of type 2 diabetes,and provide evidence-based reference for clinical treatment. METHODS:Retrieved from PubMed,EM-Base,Cochrane Library,CBM,CJFD,VIP and Wanfang database,randomized controlled trials (RCT) about the clinical efficacy and safety of insulin glargine versus insulin detemir in the treatment of type 2 diabetes were collected. Meta-analysis was performed by using Rev Man 5.2 software after data extraction and quality evaluation by Cochrane 5.1.0. RESULTS:A total of 18 RCTs,in-volving 3 638 patients were included. Results of Meta-analysis showed there was no significant difference in reducing glycosylated hemoglobin[MD=0.08,95%CI (-0.01,0.17),P=0.09];fasting blood glucose level in insulin glargine group was significantly lower thaninsulin detemir,the difference was statistically significant [MD=0.15,95%CI(0.03,0.27),P=0.02]. And there was no significant difference in the incidence of hypoglycemia [OR=0.97,95%CI(0.91,1.03),P=0.25];the degree of body mass gain ininsulin detemir was significantly lower than insulin glargine group [MD=-0.95,95%CI(-1.06,-0.85),P=0.003],but the in-cidence of injection site reactions was significantly higher than insulin glargine group [OR=2.28,95%CI(1.16,4.50),P=0.02],the differences were statistically significant. CONCLUSIONS:The insulin glargine has better efficacy,than insulin detemir with lower incidence of injection site reactions but higher degree of body mass gain than insulin detemir in the treatment of type 2 diabetes.
